Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

CIA, ferritin, ACTH, cortisol, TTH, T3, T4, insulin, CT and PTH levels were assayed radioimmunologically in the blood serum of 227 patients with lung cancer, stages I-IV, 134 cases of chronic nonspecific diseases of the lung, 28 patients with benign tumors of the lung and 30 healthy subjects. Adrenaline tests were carried out in 160 of them. Similar shifts were observed in hormone profile in both cancer and non-cancer patients. The predictive value of the hormone tests for stage I-II cancer appeared higher than in those for CIA and ferritin. However, the diagnostic value of a single test of marker proved insufficient for its practical use. Adrenaline tests identify fine disturbances in endocrine regulation and considerably raise the predictive value of such indicators as ACTH, insulin, TTH, T3, T4 and calcitonin. To assure high effectiveness of the use of basic radioimmunological data, a combination of indexes should be prepared for each case, and it should include, apart from basic levels of markers, their post-test values and indexes of reactivity.
 ...
PMID:[The dynamics of the hormonal and tumor marker levels in response to adrenaline administration in lung cancer patients]. 134 47

Endocrine abnormalities in patients with chronic renal failure are well documented. The present study aimed to assess the influence of long-term erythropoietin (EPO) therapy on endocrine abnormalities in haemodialyzed patients. Two groups of haemodialyzed patients, each of which comprised 17 subjects, were examined. The first one treated by EPO (EPO group) while the second one did not receive this hormone (NO-EPO group). A complete biochemical and hormonal check-up was performed before and at the 3, 6, 9 and 12 months of the study period. Normal values for the estimated parameters were obtained in appropriately selected sex and age-matched healthy subjects. After EPO therapy an increase of the haematocrit value from 21.8 +/- 0.9% to 32.6 +/- 0.9% was observed which was accompanied by a significant decline of plasma ferritin and saturation of transferrin. In patients of the NO-EPO group a significant although less marked rise of the haematocrit value (21.4 +/- 0.4% to 24.2 +/- 0.6%) was also noticed. EPO therapy did not change electrolytes (Na, K, Ca, inorganic phosphate), osteocalcin, creatinine, glucose and alkaline phosphatase plasma levels as well as plasma concentrations of calcium related hormones (PTH, calcitonin, 1.25(OH)2D3) and vasopressin (AVP). EPO treatment induced a significant decline of somatotropin (HGH), prolactin (PRO), follitropin (FSH), lutropin (LH), ACTH, cortisol, plasma renin activity, aldosterone, insulin (IRI), glucagon (IR-G), pancreatic polypeptide (PP) and gastrin plasma levels and an increase of plasma estradiol, testosterone and atrial natriuretic peptide (ANP). These EPO induced endocrine alterations were restricted mostly to the first 6 months of EPO administration.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Influence of long-term erythropoietin therapy on endocrine abnormalities in haemodialyzed patients. 145 6

Tiratricol has been used to suppress pituitary TSH secretion, with reported attenuation of extrapituitary thyromimetic effects. A randomized, double-blind trial was performed to define precisely the tissue-specific thyromimetic actions of tiratricol. Ten athyreotic patients, treated for thyroid carcinoma, were randomly assigned to receive L-T4 sodium 0.7 micrograms/kg daily and either tiratricol 10 micrograms/kg or placebo twice daily. The daily dose of L-T4 was increased by 25-50 micrograms increments until the TRH-stimulated TSH level was less than 0.1 mU/L. After measurement of biochemical and physiological parameters of thyroid hormone actions, patients crossed treatment groups. Patients required 46% less L-T4 to achieve equivalent TSH suppression when taking tiratricol. Hepatic effects were enhanced by tiratricol administration, with significant increases in sex hormone binding globulin and ferritin concentrations, 14% and 37%, respectively. Levels of serum cholesterol, LDL cholesterol, and apolipoprotein B were reduced by 7%, 10%, and 13%, respectively, during tiratricol therapy. Triglyceride levels also declined, but there were no changes of high density lipoprotein cholesterol or apolipoproteins AI and AII. Resting metabolic rate, body weight, urea nitrogen excretion, and symptoms did not differ between the two treatment regimens. Cardiovascular function, as reflected by mean arterial pressure and pulse wave arrival time, was not different during tiratricol therapy. Skeletal metabolic activity was affected by tiratricol, with marked elevation of osteocalcin without significant change in serum calcium, PTH, and urinary calcium and hydroxyproline excretion. Tiratricol has increased hepatic and skeletal actions of potential therapeutic value, but does not have enhanced thyromimetic activity specific to the pituitary gland.
 ...
PMID:Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects. 151 83

Recombinant human erythropoietin (rHuEpo) is an effective therapy for anaemia in most patients with end-stage renal disease (ESRD). However, there remain a minority of patients with ESRD who are resistant to the effects of rHuEpo. The present study examined the role of aluminium overload and hyperparathyroidism of the biological effects of rHuEpo. Twenty-two patients aged 26-74 (mean 53 +/- SD 15.5) received rHuEpo 50-200 U/kg per week for 16.5 +/- 8.0 months (range 3-27). Haemoglobin was maintained at 11.5-13.0 g/dl by appropriate dose adjustment. Iron supplements were provided to maintain serum ferritin greater than 200 ng/ml. The mean time to rHuEpo response (Hb greater than 2 g/dl over baseline) was 6.1 +/- 2.6 weeks. Mean pretreatment serum aluminium correlated with time to Hb response (r = 0.48; P less than 0.05) and pretreatment mean corpuscular volume (r = 0.43; P less than 0.05) but not with eventual rHuEpo maintenance dose. PTH did not correlate with either Hb response or eventual maintenance rHuEpo dose. In summary, elevated serum aluminium concentrations were associated with an initial resistance to the biological effects of rHuEpo but had no effect on long-term dose requirements. In contrast, no impact of PTH on either immediate or long-term rHuEpo dose was evident.
 ...
PMID:The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients. 187 Jul 50

In order to clarify possible factors responsible for varying responses in uremic patients treated with recombinant human erythropoietin (rHuEPO), we determined the inhibitory effects of ten uremic sera on the erythroid progenitors (CFU-E) and erythroid bursts (BFU-E). We also measured plasma EPO titers, Fe, UIBC, ferritin, PTH-C, beta 2-microglobulin, and aluminum in all ten patients. The inhibitor of CFU-E but not BFU-E, was present in the serum of the single anemic patient whose recovery took longer after the administration of rHuEPO. He did not have such conditions as iron deficiency, excess of aluminum, or chronic inflammation. The remaining patients, who had no CFU-E or BFU-E inhibitors, were good responders to rHuEPO. In none of ten patients were there inhibitors of granulocyte-macrophage progenitors (CFU-GM) or any differences in the other parameters. Although the inhibitory factor of CFU-E can be overcome with a larger dose, its prior determination may be useful to set out minimal effective dose of EPO treatment.
 ...
PMID:The inhibitory factors of hematopoiesis in chronic hemodialysis patients treated with recombinant human erythropoietin. 224 92

In order to examine the efficacy and safety of long-term and low-dose desferrioxamine (DFO) therapy against hyperaluminemia and the clinical symptoms associated with hyperaluminemia, 4 patients (3 men and 1 woman, 40-62 years old, period of hemodialysis: 69-189 months) undergoing maintenance hemodialysis were treated by DFO (0.5 g/week) and hemodiafiltration for 27 weeks. 1 patient had only hyperaluminemia, but other 3 patients had refractory ostalgia and arthralgia associated with hyperaluminemia. Clinically, ostalgia and arthralgia disappeared within 1 month after the initiation of treatment. The decrease of serum aluminum level was recognized in all patients (74 +/- 7 micrograms/l to 52 +/- 7 micrograms/l). Also the decrease of delta aluminium was recognized in 2 patients. Serum iron levels did not change, but unsaturable iron binding capacity levels increased slightly. Serum ferritin level decreased in 1 patient. Serum PTH-C levels increased slightly in 3 patients. Serum total protein and albumin levels did not change. Serum transferrin levels increased slightly. Bone mineral contents were measured by microdensitometry method. In 1 patient with only hyperaluminemia, MCI and S.GS/D ameliorated remarkably. Side effects were not recognized in all patients during the course of treatment with DFO. In conclusion, it was thought that the treatment of long-term and low-dose DFO was effective and safe against hyperaluminemia and aluminium intoxication in patients undergoing maintenance hemodialysis.
 ...
PMID:[Efficacy and safety of long-term and low-dose desferrioxamine therapy against hyperaluminemia and the clinical symptoms associated with hyperaluminemia in patients undergoing maintenance hemodialysis]. 273 24

In 24 hemodialyzed uremic patients the serum levels of iron, ferritin, transferrin and parathyroid hormone were determined and the iron absorption in the gastrointestinal tract after an oral load was studied. Moderately elevated iron levels but extremely high concentrations of ferritin in the blood serum were found. A significant positive correlation was found between serum ferritin and iron levels as well as between serum ferritin and the cumulative volume of transfused blood. No correlation was stated between serum PTH and ferritin levels. No abnormality in iron absorption in the gastrointestinal tract was found. The obtained results suggest the necessity of monitoring ferritin levels as a reliable indicator of whole body iron stores in hemodialyzed uremic patients. Hyperfunction of the parathyroid glands does not seem to play an important role in the pathogenesis of abnormal iron metabolism in hemodialyzed patients.
 ...
PMID:[Iron balance in hemodialysis in chronic uremia]. 340 Mar 53

It appears well established that a microcytic, hypochromic anaemia is present in patients receiving regular haemodialysis treatment, who also suffer from chronic aluminium intoxication. This characteristic anaemia is slightly improved following deionization or reverse-osmosis treatment of dialysate water. Iron deficiency has been tentatively excluded as a cause of this anaemia by measurement of serum ferritin levels. The exact mechanisms involved in the pathogenesis of this anaemia are still to be fully elucidated but a disturbance in haem synthesis and porphyrin metabolism seems probable, and secondary effects of PTH in the bone marrow may be involved. Evidence has accumulated that aluminium is the most likely ion responsible for this anaemia but other ions, trace metals in excess or deficiency and potentially toxic substances cannot be excluded yet.
 ...
PMID:Aluminium-induced anaemia in haemodialysis patients. 396 84

The results of studies on ventilation and capillary blood flow are analyzed in 89 lung carcinoma patients and 28 patients with nonmalignant lung diseases by using 133Xe and 99mTc-MAA. The studies were conducted with the help of scintillation radiometers: multidetector unit and a gamma-chamber. The concentration in the blood serum of biologically active agents: CEA, PTH, immunoglobulin E, ferritin, hydrocortisone and beta2-microglobulin was determined in 76 cancer patients and 19 patients with nontumorous lung diseases. It has been established that visualization with 99mTc-MMA and studies with 133Xe are of utmost informative value. There was not a single specific marker for lung carcinoma that could be independently used for the diagnosis of this pathology. It is appropriate that they should be used in combination with other radionuclide methods and instrumental examination. Besides, they can be recommended for control over therapeutic efficacy.
 ...
PMID:[Radionuclide complex in vitro studies in the diagnosis of lung cancer]. 622 98

Serum erythropoietin (EPO) was measured in 64 children with chronic renal failure (CRF) by means of the fetal mouse liver cell assay. The results were compared with two control groups consisting of 20 healthy children and 10 with nonrenal anemia. EPO was analyzed according to the mode of treatment and the degree of uremia, anemia, hypoxemia, hyperparathyroidism, and body iron load. Mean EPO was 36 U/liter on conservative treatment (CT) (N = 30), similar to that in healthy children (35 U/liter) and in 15 children with renal transplants (TP, 39 U/liter), but significantly higher than that in 19 patients on regular dialysis (RDT; 16 U/liter) and lower than that in children with nonrenal anemia but with similar hemoglobin (230 U/liter). On CT, EPO was higher with severe uremia (SCr greater than 4 mg/dl) compared with moderate CRF and was inversely correlated with hemoglobin, but on a lower level compared with control, whereas on RDT the correlation became positive. By serial measurements, the decrease of EPO from CT to RDT was confirmed. An inverse relationship between EPO and p50 or the oxygen transport index was detected only on CT and after TP. EPO was inversely correlated with serum ferritin levels on HD. Between EPO and PTH, no correlation was found. Data demonstrate a negative feedback between EPO and the degree of hypoxia in children with CRF. On CT, this regulatory mechanism of erythropoiesis is acting on a lower level than it does in control subjects and is lost on RDT.
 ...
PMID:Serum erythropoietin levels in children with chronic renal failure. 658 79


1 2 3 4 Next >>